Dystrophic Epidermolysis Bullosa Treatment Receives Fast Track Designation

The FDA has recently granted the Fast Track designation to AGLE-102, a treatment for dystrophic epidermolysis bullosa. This designation will allow for the treatment to reach patients at a quicker…

Continue Reading Dystrophic Epidermolysis Bullosa Treatment Receives Fast Track Designation

Patient Dosing Begins in VIITAL Study of EB-101, a Treatment for Recessive Dystrophic Epidermolysis Bullosa

The first patient has been dosed in the third phase of the VIITAL study, which is intended to evaluate the effectiveness of EB-101. This medication is a gene-corrected cell therapy…

Continue Reading Patient Dosing Begins in VIITAL Study of EB-101, a Treatment for Recessive Dystrophic Epidermolysis Bullosa

New Gene Discovered as Cause of Pretibial Dystrophic Epidermolysis Bullosa

Dystrophic epidermolysis bullosa (DEB) is a condition that has many sub-types, one of which is pretibial. The COL7A1 gene, which is responsible for producing VII collagen, is the cause of…

Continue Reading New Gene Discovered as Cause of Pretibial Dystrophic Epidermolysis Bullosa
Partnership Will Allow The Development of New Drug For Dystrophic Epidermolysis Bullosa
rawpixel / Pixabay

Partnership Will Allow The Development of New Drug For Dystrophic Epidermolysis Bullosa

According to a story from pm360online.com, the drug development company ProQR Therapeutics N.V. will be partnering with EB Research Partnership (EBRP) and EB Medical Research Foundation (EBMRF) in order to…

Continue Reading Partnership Will Allow The Development of New Drug For Dystrophic Epidermolysis Bullosa
Close Menu